| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
From the Canadian Field Epidemiology Program (Gilbert, Siushansian), Public Health Agency of Canada, Ottawa, Ont.; the Centre for Antimicrobial Resistance (Zhang, Laupland, Conly), Calgary Laboratory Services (Gregson, Zhang, Elsayed, Laupland, Conly), Calgary Health Region (MacDonald, Gregson, Zhang, Elsayed, Laupland, T. Louie, M. Louie, Hope, Gillespie, Nielsen, Wheeler, Conly) and the Departments of Pathology and Laboratory Medicine (Gregson, Zhang, Elsayed, Laupland, T. Louie, M. Louie, Conly), Medicine (Gregson, Zhang, Laupland, T. Louie, M. Louie, Conly), Microbiology and Infectious Diseases (Zhang, Elsayed, T. Louie, M. Louie, Conly) and Community Health Sciences (MacDonald, Laupland), University of Calgary, Calgary; Alberta Provincial Laboratory for Public Health (M. Louie), Alberta Health and Wellness (Honish, Keays), Edmonton, Alta.; and the National Microbiological Laboratory (Mulvey), Public Health Agency of Canada, Winnipeg, Man.
Correspondence to: Dr. John Conly, Department of Medicine, Centre for Antimicrobial Resistance, University of Calgary, Calgary Health Region, and Calgary Laboratory Services, Calgary AB T2N 2T9; fax 403 944-1095; jconly{at}ucalgary.ca
Background: The USA300 strain of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) can cause severe infection and is increasingly recognized as a cause of community outbreaks. In 2004, an outbreak was identified in the Calgary Health Region (CHR).
Methods: MRSA isolates were identified with standard methods at a central regional laboratory and typed via pulsed-field gel electrophoresis (PFGE). Isolates were tested by PCR for mecA, PantonValentine leukocidin (PVL), SCCmec, and spa genes. Cases were defined as such if a clinical isolate of the USA300 strain was noted between January 1 and September 30, 2004, and the patient had lived or traveled in CHR within 2 years before symptom onset. Demographic, clinical and risk data on all such cases were collected from several sources for statistical analysis. A case was defined as high-risk if the patient had a history of drug use, homelessness or incarceration.
Results: Of 40 isolates with the USA300 PFGE pattern, all tested positive for PVL, SCCmec type IVa and spa type 008. Almost all infections (39/40, 98%) involved skin and soft tissues, except for 1 death from necrotizing hemorrhagic pneumonia; a notable proportion (38%) required hospital admission or intravenous antimicrobial therapy. The outbreak centred on the high-risk population in CHR (70%; risk ratio 169.4, 95% confidence interval 86.1333.0).
Interpretation: People with histories of illicit drug use, homelessness or recent incarceration were at highest risk for infection with CA-MRSA. The emergence and spread of this virulent strain has important implications for treatment and public health in Canada.
Related Article
This article has been cited by other articles:
![]() |
J. J. Hilliard, J. Fernandez, J. Melton, M. J. Macielag, R. Goldschmidt, K. Bush, and D. Abbanat In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2028 - 2033. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Mulvey PhD and A. E. Simor MD Antimicrobial resistance in hospitals: How concerned should we be? Can. Med. Assoc. J., February 17, 2009; 180(4): 408 - 415. [Full Text] [PDF] |
||||
![]() |
M. Z. David, C. Mennella, M. Mansour, S. Boyle-Vavra, and R. S. Daum Predominance of Methicillin-Resistant Staphylococcus aureus among Pathogens Causing Skin and Soft Tissue Infections in a Large Urban Jail: Risk Factors and Recurrence Rates J. Clin. Microbiol., October 1, 2008; 46(10): 3222 - 3227. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Zhanel, M. DeCorby, N. Laing, B. Weshnoweski, R. Vashisht, F. Tailor, K. A. Nichol, A. Wierzbowski, P. J. Baudry, J. A. Karlowsky, et al. Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006 Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1430 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takano, W. Higuchi, T. Otsuka, T. Baranovich, S. Enany, K. Saito, H. Isobe, S. Dohmae, K. Ozaki, M. Takano, et al. Novel Characteristics of Community-Acquired Methicillin-Resistant Staphylococcus aureus Strains Belonging to Multilocus Sequence Type 59 in Taiwan Antimicrob. Agents Chemother., March 1, 2008; 52(3): 837 - 845. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Diep, H. F. Chambers, C. J. Graber, J. D. Szumowski, L. G. Miller, L. L. Han, J. H. Chen, F. Lin, J. Lin, T. H. Phan, et al. Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus Clone USA300 in Men Who Have Sex with Men Ann Intern Med, February 19, 2008; 148(4): 249 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. N. Al-Rawahi, A. G. Schreader, S. D. Porter, D. L. Roscoe, R. Gustafson, and E. A. Bryce Methicillin-Resistant Staphylococcus aureus Nasal Carriage among Injection Drug Users: Six Years Later J. Clin. Microbiol., February 1, 2008; 46(2): 477 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Gupta, A. MacIntyre, G. Vanasse, and L.-M. Dembry Trends in Prescribing -Lactam Antibiotics for Treatment of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections J. Clin. Microbiol., December 1, 2007; 45(12): 3930 - 3934. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Simor, T. L. Stuart, L. Louie, C. Watt, M. Ofner-Agostini, D. Gravel, M. Mulvey, M. Loeb, A. McGeer, E. Bryce, et al. Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3880 - 3886. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Korownyk and G. M. Allan Evidence-based approach to abscess management Can Fam Physician, October 1, 2007; 53(10): 1680 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Christianson, G. R. Golding, J. Campbell, the Canadian Nosocomial Infection Surveillance Pro, and M. R. Mulvey Comparative Genomics of Canadian Epidemic Lineages of Methicillin-Resistant Staphylococcus aureus J. Clin. Microbiol., June 1, 2007; 45(6): 1904 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. D. Pitout, D. L. Church, D. B. Gregson, B. L. Chow, M. McCracken, M. R. Mulvey, and K. B. Laupland Molecular Epidemiology of CTX-M-Producing Escherichia coli in the Calgary Health Region: Emergence of CTX-M-15-Producing Isolates Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1281 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. van der Mee-Marquet, C. Epinette, J. Loyau, L. Arnault, A.-S. Domelier, B. Losfelt, N. Girard, R. Quentin, and and the Bloodstream Infection Study Group of the R Staphylococcus aureus Strains Isolated from Bloodstream Infections Changed Significantly in 2006 J. Clin. Microbiol., March 1, 2007; 45(3): 851 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hawkes, M. Barton, J. Conly, L. Nicolle, C. Barry, and E. L. Ford-Jones Community-associated MRSA: Superbug at our doorstep Can. Med. Assoc. J., January 2, 2007; 176(1): 54 - 56. [Full Text] [PDF] |
||||
![]() |
J. M. Embil, Z. J. Oliver, M. R. Mulvey, and E. Trepman A man with recurrent furunculosis Can. Med. Assoc. J., July 18, 2006; 175(2): 143 - 143. [Full Text] [PDF] |
||||
![]() |
L. Nicolle Community-acquired MRSA: a practitioner's guide Can. Med. Assoc. J., July 18, 2006; 175(2): 145 - 145. [Full Text] [PDF] |
||||
![]() |
U. D. Allen Public health implications of MRSA in Canada Can. Med. Assoc. J., July 18, 2006; 175(2): 161 - 161. [Full Text] [PDF] |
||||
Read all eLetters